<?xml version="1.0" encoding="UTF-8"?>
<GoldLabel drug="XTANDI">
  <Text>
    <Section id="S1" name="adverse reactions">  6 ADVERSE REACTIONS

  The following is discussed in more detail in other sections of the labeling:

 *    Seizure [see  Warnings and Precautions  (  5.1  )]  
 *    Posterior Reversible Encephalopathy Syndrome (PRES) [see  Warnings and Precautions  (  5.2  )]  
      EXCERPT:   The most common adverse reactions (&gt;= 10%) are asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo. (  6.1  )
 

   To report SUSPECTED ADVERSE REACTIONS, contact Astellas Pharma US, Inc. at 1-800-727-7003 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch  .  

 

  6.1 Clinical Trial Experience

  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

 Three randomized clinical trials enrolled patients with metastatic prostate cancer that has progressed on androgen deprivation therapy (GnRH therapy or bilateral orchiectomy), a disease setting that is also defined as metastatic CRPC. Two trials were placebo-controlled (Studies 1 and 2), and one trial was bicalutamide-controlled (Study 3). In Studies 1 and 2, patients received XTANDI 160 mg or placebo orally once daily. In Study 3, patients received XTANDI 160 mg or bicalutamide 50 mg orally once daily. All patients continued androgen deprivation therapy. Patients were allowed, but not required, to take glucocorticoids.

 The most common adverse reactions (&gt;= 10%) that occurred more commonly (&gt;= 2% over placebo) in the XTANDI-treated patients from the two randomized placebo-controlled clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.

   Study 1: XTANDI versus Placebo in Metastatic CRPC Following Chemotherapy  

 Study 1 enrolled 1199 patients with metastatic CRPC who had previously received docetaxel. The median duration of treatment was 8.3 months with XTANDI and 3.0 months with placebo. During the trial, 48% of patients on the XTANDI arm and 46% of patients on the placebo arm received glucocorticoids.

 Grade 3 and higher adverse reactions were reported among 47% of XTANDI-treated patients and 53% of placebo-treated patients. Discontinuations due to adverse events were reported for 16% of XTANDI-treated patients and 18% of placebo-treated patients. The most common adverse reaction leading to treatment discontinuation was seizure, which occurred in 0.9% of the XTANDI-treated patients compared to none (0%) of the placebo-treated patients.  Table 1  shows adverse reactions reported in Study 1 that occurred at a &gt;= 2% higher frequency in the XTANDI arm compared to the placebo arm.

 Table 1. Adverse Reactions in Study 1 
                                             XTANDI  N = 800    Placebo  N = 399    
  Grade 1-4a  (%)                            Grade 3-4  (%)    Grade 1-4  (%)    Grade 3-4  (%)    
  General Disorders                          
      Asthenic Conditionsb                   50.6             9.0              44.4             9.3              
      Peripheral Edema                       15.4             1.0              13.3             0.8              
  Musculoskeletal And Connective Tissue Disorders    
      Back Pain                              26.4             5.3              24.3             4.0              
      Arthralgia                             20.5             2.5              17.3             1.8              
      Musculoskeletal Pain                   15.0             1.3              11.5             0.3              
      Muscular Weakness                      9.8              1.5              6.8              1.8              
      Musculoskeletal Stiffness              2.6              0.3              0.3              0.0              
  Gastrointestinal Disorders                 
      Diarrhea                               21.8             1.1              17.5             0.3              
  Vascular Disorders                         
      Hot Flush                              20.3             0.0              10.3             0.0              
      Hypertension                           6.4              2.1              2.8              1.3              
  Nervous System Disorders                   
      Headache                               12.1             0.9              5.5              0.0              
      Dizzinessc                             9.5              0.5              7.5              0.5              
      Spinal Cord Compression     and Cauda Equina Syndrome    7.4              6.6              4.5              3.8              
      Paresthesia                            6.6              0.0              4.5              0.0              
      Mental Impairment Disordersd           4.3              0.3              1.8              0.0              
      Hypoesthesia                           4.0              0.3              1.8              0.0              
  Infections And Infestations                
      Upper Respiratory Tract     Infectione    10.9             0.0              6.5              0.3              
      Lower Respiratory Tract And     Lung Infectionf    8.5              2.4              4.8              1.3              
  Psychiatric Disorders                      
      Insomnia                               8.8              0.0              6.0              0.5              
      Anxiety                                6.5              0.3              4.0              0.0              
  Renal And Urinary Disorders                
      Hematuria                              6.9              1.8              4.5              1.0              
      Pollakiuria                            4.8              0.0              2.5              0.0              
  Injury, Poisoning And Procedural Complications    
      Fall                                   4.6              0.3              1.3              0.0              
      Non-pathologic Fractures               4.0              1.4              0.8              0.3              
  Skin And Subcutaneous Tissue Disorders     
      Pruritus                               3.8              0.0              1.3              0.0              
      Dry Skin                               3.5              0.0              1.3              0.0              
  Respiratory Disorders                      
      Epistaxis                              3.3              0.1              1.3              0.3              
  a    CTCAE v4  b    Includes asthenia and fatigue.  c    Includes dizziness and vertigo.  d    Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention.  e    Includes nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis.  f    Includes pneumonia, lower respiratory tract infection, bronchitis, and lung infection.    
             Study 2: XTANDI versus Placebo in Chemotherapy-naive Metastatic CRPC  
 

 Study 2 enrolled 1717 patients with metastatic CRPC who had not received prior cytotoxic chemotherapy, of whom 1715 received at least one dose of study drug. The median duration of treatment was 17.5 months with XTANDI and 4.6 months with placebo. Grade 3-4 adverse reactions were reported in 44% of XTANDI-treated patients and 37% of placebo-treated patients. Discontinuations due to adverse events were reported for 6% of XTANDI-treated patients and 6% of placebo-treated patients. The most common adverse reaction leading to treatment discontinuation was fatigue/asthenia, which occurred in 1% of patients on each treatment arm.  Table 2  includes adverse reactions reported in Study 2 that occurred at a &gt;= 2% higher frequency in the XTANDI arm compared to the placebo arm.

 Table 2. Adverse Reactions in Study 2 
                                              XTANDI    N = 871      Placebo    N = 844     
   Grade 1-4  a      (%)                      Grade 3-4    (%)      Grade 1-4    (%)      Grade 3-4    (%)     
  
  General Disorders                          
      Asthenic Conditionsb                   46.9             3.4              33.0             2.8             
      Peripheral Edema                       11.5             0.2              8.2              0.4             
  Musculoskeletal And Connective Tissue Disorders    
      Back Pain                              28.6             2.5              22.4             3.0             
      Arthralgia                             21.4             1.6              16.1             1.1             
  Gastrointestinal Disorders                 
      Constipation                           23.2             0.7              17.3             0.4             
      Diarrhea                               16.8             0.3              14.3             0.4             
  Vascular Disorders                         
      Hot Flush                              18.0             0.1              7.8              0.0             
      Hypertension                           14.2             7.2              4.1              2.3             
  Nervous System Disorders                   
      Dizzinessc                             11.3             0.3              7.1              0.0             
      Headache                               11.0             0.2              7.0              0.4             
      Dysgeusia                              7.6              0.1              3.7              0.0             
      Mental Impairment Disordersd           5.7              0.0              1.3              0.1             
      Restless Legs Syndrome                 2.1              0.1              0.4              0.0             
  Respiratory Disorders                      
      Dyspneae                               11.0             0.6              8.5              0.6             
  Infections And Infestations                
      Upper Respiratory Tract     Infectionf    16.4             0.0              10.5             0.0             
      Lower Respiratory Tract And     Lung Infectiong    7.9              1.5              4.7              1.1             
  Psychiatric Disorders                      
      Insomnia                               8.2              0.1              5.7              0.0             
  Renal And Urinary Disorders                
      Hematuria                              8.8              1.3              5.8              1.3             
  Injury, Poisoning And Procedural Complications    
      Fall                                   12.7             1.6              5.3              0.7             
      Non-Pathological Fracture              8.8              2.1              3.0              1.1             
  Metabolism and Nutrition Disorders         
      Decreased Appetite                     18.9             0.3              16.4             0.7             
  Investigations                             
      Weight Decreased                       12.4             0.8              8.5              0.2             
  Reproductive System and Breast disorders    
      Gynecomastia                           3.4              0.0              1.4              0.0             
  a    CTCAE v4  b    Includes asthenia and fatigue.  c    Includes dizziness and vertigo.  d    Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention.  e    Includes dyspnea, exertional dyspnea, and dyspnea at rest.  f    Includes nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis.  g    Includes pneumonia, lower respiratory tract infection, bronchitis, and lung infection.    
             Study 3: XTANDI versus Bicalutamide in Chemotherapy-naive Metastatic CRPC  
 

 Study 3 enrolled 375 patients with metastatic CRPC who had not received prior cytotoxic chemotherapy, of whom 372 received at least one dose of study drug.  The median duration of treatment was 11.6 months with XTANDI and 5.8 months with bicalutamide. Discontinuations with an adverse event as the primary reason were reported for 7.6% of XTANDI-treated patients and 6.3% of bicalutamide-treated patients. The most common adverse reactions leading to treatment discontinuation were back pain and pathological fracture, which occurred in 3.8% of XTANDI-treated patients for each event and in 2.1% and 1.6% of bicalutamide-treated patients, respectively.  Table 3  shows overall and common adverse reactions (&gt;= 10%) in XTANDI-treated patients.

 Table 3. Adverse Reactions in Study 3 
                                              XTANDI    (N=183)      Bicalutamide    (N=189)     
   Grade 1-4  a      (%)                      Grade 3-4    (%)      Grade 1-4  a      (%)      Grade 3-4    (%)     
  
  Overall                                    94.0             38.8             94.2             37.6             
  General Disorders                          
      Asthenic Conditionsb                   31.7             1.6              22.8             1.1              
  Musculoskeletal And Connective Tissue Disorders    
      Back Pain                              19.1             2.7              18.0             1.6              
      Musculoskeletal Painc                  16.4             1.1              14.3             0.5              
  Vascular Disorders                         
      Hot Flush                              14.8             0                11.1             0                
      Hypertension                           14.2             7.1              7.4              4.2              
  Gastrointestinal Disorders                 
      Nausea                                 14.2             0                17.5             0                
      Constipation                           12.6             1.1              13.2             0.5              
      Diarrhea                               11.5             0                9.0              1.1              
  Infections And Infestations                
      Upper Respiratory Tract Infectiond     12.0             0                6.3              0.5              
  Investigational                            
      Weight Loss                            10.9             0.5              7.9              0.5              
  a    CTCAE v 4b    Including asthenia and fatigue.c    Including musculoskeletal pain and pain in extremity d    Including nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis    
             Laboratory Abnormalities  
 

 In the two randomized placebo-controlled clinical trials, Grade 1-4 neutropenia occurred in 15% of patients treated with XTANDI (1% Grade 3-4) and in 6% of patients treated with placebo (0.5% Grade 3-4). The incidence of Grade 1-4 thrombocytopenia was 6% of patients treated with XTANDI (0.3% Grade 3-4) and 5% of patients treated with placebo (0.5% Grade 3-4). Grade 1-4 elevations in ALT occurred in 10% of patients treated with XTANDI (0.2% Grade 3-4) and 16% of patients treated with placebo (0.2% Grade 3-4). Grade 1-4 elevations in bilirubin occurred in 3% of patients treated with XTANDI (0.1% Grade 3-4) and 2% of patients treated with placebo (no Grade 3-4).

   Infections  

 In Study 1, 1% of patients treated with XTANDI compared to 0.3% of patients treated with placebo died from infections or sepsis. In Study 2, 1 patient in each treatment group (0.1%) had an infection resulting in death.

   Falls and Fall-related Injuries  

 In the two randomized placebo-controlled clinical trials, falls including fall-related injuries, occurred in 9% of patients treated with XTANDI compared to 4% of patients treated with placebo. Falls were not associated with loss of consciousness or seizure. Fall-related injuries were more severe in patients treated with XTANDI and included non-pathologic fractures, joint injuries, and hematomas.

   Hypertension  

 In the two randomized placebo-controlled trials, hypertension was reported in 11% of patients receiving XTANDI and 4% of patients receiving placebo. No patients experienced hypertensive crisis. Medical history of hypertension was balanced between arms. Hypertension led to study discontinuation in &lt; 1% of patients in each arm.

   6.2 Post-Marketing Experience

  The following additional adverse reactions have been identified during post approval use of XTANDI. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.

   Body as a Whole:  hypersensitivity (tongue edema, lip edema, and pharyngeal edema)

   Gastrointestinal Disorders:  vomiting

   Neurological Disorders:  posterior reversible encephalopathy syndrome (PRES)

   Skin and Subcutaneous Tissue Disorders:  rash

</Section>
    <Section id="S2" name="warnings and precautions">   5 WARNINGS AND PRECAUTIONS

   EXCERPT:    *    Seizure occurred in 0.5% of patients receiving XTANDI. In patients with predisposing factors, seizures were reported in 2.2% of patients. Permanently discontinue XTANDI in patients who develop a seizure during treatment. (  5.1  ) 
 *    Posterior reversible encephalopathy syndrome (PRES): Discontinue XTANDI. (  5.2  ) 
    
 

    5.1 Seizure  

   Seizure occurred in 0.5% of patients receiving XTANDI in clinical studies. In these trials patients with predisposing factors for seizure were generally excluded. Seizure occurred from 31 to 603 days after initiation of XTANDI. Patients experiencing seizure were permanently discontinued from therapy and all seizure events resolved.  

  In a single-arm trial designed to assess the risk of seizure in patients with pre-disposing factors for seizure, 8 of 366 (2.2%) XTANDI-treated patients experienced a seizure. Three of the 8 patients experienced a second seizure during continued treatment with XTANDI after their first seizure resolved. It is unknown whether anti-epileptic medications will prevent seizures with XTANDI. Patients in the study had one or more of the following pre-disposing factors: the use of medications that may lower the seizure threshold (~ 54%), history of traumatic brain or head injury (~ 28%), history of cerebrovascular accident or transient ischemic attack (~ 24%), and Alzheimer's disease, meningioma, or leptomeningeal disease from prostate cancer, unexplained loss of consciousness within the last 12 months, past history of seizure, presence of a space occupying lesion of the brain, history of arteriovenous malformation, or history of brain infection (all &lt; 5%). Approximately 17% of patients had more than one risk factor.  

  Advise patients of the risk of developing a seizure while receiving XTANDI and of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others.  

  Permanently discontinue XTANDI in patients who develop a seizure during treatment.  

    5.2 Posterior Reversible Encephalopathy Syndrome (PRES)

  There have been reports of posterior reversible encephalopathy syndrome (PRES) in patients receiving XTANDI [see  Adverse Reactions  (  6.2  )]  . PRES is a neurological disorder which can present with rapidly evolving symptoms including seizure, headache, lethargy, confusion, blindness, and other visual and neurological disturbances, with or without associated hypertension. A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic resonance imaging (MRI). Discontinue XTANDI in patients who develop PRES.

</Section>
  </Text>
  <IgnoredRegions>
    <IgnoredRegion len="19" name="heading" section="S1" start="2" />
    <IgnoredRegion len="26" name="heading" section="S2" start="3" />
    <IgnoredRegion len="344" name="excerpt" section="S2" start="33" />
    <IgnoredRegion len="467" name="excerpt" section="S1" start="270" />
    <IgnoredRegion len="14" name="heading" section="S2" start="384" />
    <IgnoredRegion len="29" name="heading" section="S1" start="741" />
    <IgnoredRegion len="55" name="heading" section="S2" start="2058" />
    <IgnoredRegion len="29" name="heading" section="S1" start="16734" />
  </IgnoredRegions>
  <Mentions>
    <Mention id="M191" len="7" reason="from_drug_use" section="S1" start="109" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Seizure" meddra_llt_id="10039906" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M192" len="50" reason="from_drug_use" section="S1" start="168" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Posterior reversible encephalopathy syndrome" meddra_llt_id="10071066" meddra_pt="Posterior reversible encephalopathy syndrome" meddra_pt_id="10071066" />
    </Mention>
    <Mention id="M2" len="26" reason="indication" section="S1" start="1096" type="Not_AE_Candidate">
      <Normalization meddra_llt="Prostate cancer metastatic" meddra_llt_id="10036909" meddra_pt="Prostate cancer metastatic" meddra_pt_id="10036909" />
    </Mention>
    <Mention id="M3" len="15" reason="indication" section="S1" start="1258" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hormone-refractory prostate cancer" meddra_llt_id="10062904" meddra_pt="Hormone-refractory prostate cancer" meddra_pt_id="10062904" />
    </Mention>
    <Mention id="M53" len="8" reason="from_drug_use" section="S1" start="1857" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Asthenia" meddra_llt_id="10003549" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M54" len="7" reason="from_drug_use" section="S1" start="1866" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M55" len="9" reason="from_drug_use" section="S1" start="1875" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain back" meddra_llt_id="10033380" meddra_pt="Back pain" meddra_pt_id="10003988" />
    </Mention>
    <Mention id="M56" len="18" reason="from_drug_use" section="S1" start="1886" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Decreased appetite" meddra_llt_id="10061428" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M57" len="12" reason="from_drug_use" section="S1" start="1906" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M58" len="10" reason="from_drug_use" section="S1" start="1920" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Arthralgia" meddra_llt_id="10003239" meddra_pt="Arthralgia" meddra_pt_id="10003239" />
    </Mention>
    <Mention id="M59" len="8" reason="from_drug_use" section="S1" start="1932" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M60" len="9" reason="from_drug_use" section="S1" start="1942" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hot flush" meddra_llt_id="10060800" meddra_pt="Hot flush" meddra_pt_id="10060800" />
    </Mention>
    <Mention id="M61" len="33" reason="from_drug_use" section="S1" start="1953" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper respiratory tract infection" meddra_llt_id="10046306" meddra_pt="Upper respiratory tract infection" meddra_pt_id="10046306" />
    </Mention>
    <Mention id="M62" len="16" reason="from_drug_use" section="S1" start="1988" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Peripheral edema" meddra_llt_id="10034570" meddra_pt="Oedema peripheral" meddra_pt_id="10030124" />
    </Mention>
    <Mention id="M63" len="7" reason="from_drug_use" section="S1" start="2006" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspnea" meddra_llt_id="10013963" meddra_pt="Dyspnoea" meddra_pt_id="10013968" />
    </Mention>
    <Mention id="M64" len="20" reason="from_drug_use" section="S1" start="2015" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Musculoskeletal pain" meddra_llt_id="10028391" meddra_pt="Musculoskeletal pain" meddra_pt_id="10028391" />
    </Mention>
    <Mention id="M65" len="16" reason="from_drug_use" section="S1" start="2037" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight decreased" meddra_llt_id="10047895" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M66" len="8" reason="from_drug_use" section="S1" start="2055" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Headache" meddra_llt_id="10019211" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Mention>
    <Mention id="M67" len="12" reason="from_drug_use" section="S1" start="2065" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M68" len="9" reason="from_drug_use" section="S1" start="2083" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M69" len="7" reason="from_drug_use" section="S1" start="2093" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vertigo" meddra_llt_id="10047340" meddra_pt="Vertigo" meddra_pt_id="10047340" />
    </Mention>
    <Mention id="M4" len="15" reason="indication" section="S1" start="2219" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hormone-refractory prostate cancer" meddra_llt_id="10062904" meddra_pt="Hormone-refractory prostate cancer" meddra_pt_id="10062904" />
    </Mention>
    <Mention id="M70" len="7" reason="from_drug_use" section="S1" start="2806" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Seizure" meddra_llt_id="10039906" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M8" len="17" reason="general_term" section="S1" start="3295" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M193" len="19" reason="from_drug_use" section="S1" start="3345" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Asthenia" meddra_llt_id="10003549" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M71" len="16" reason="from_drug_use" section="S1" start="3459" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Peripheral edema" meddra_llt_id="10034570" meddra_pt="Oedema peripheral" meddra_pt_id="10030124" />
    </Mention>
    <Mention id="M9" len="47" reason="general_term" section="S1" start="3569" type="NonOSE_AE">
      <Normalization meddra_llt="Musculoskeletal disorder" meddra_llt_id="10048592" meddra_pt="Musculoskeletal disorder" meddra_pt_id="10048592" />
    </Mention>
    <Mention id="M72" len="9" reason="from_drug_use" section="S1" start="3627" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain back" meddra_llt_id="10033380" meddra_pt="Back pain" meddra_pt_id="10003988" />
    </Mention>
    <Mention id="M73" len="10" reason="from_drug_use" section="S1" start="3741" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Arthralgia" meddra_llt_id="10003239" meddra_pt="Arthralgia" meddra_pt_id="10003239" />
    </Mention>
    <Mention id="M74" len="20" reason="from_drug_use" section="S1" start="3855" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Musculoskeletal pain" meddra_llt_id="10028391" meddra_pt="Musculoskeletal pain" meddra_pt_id="10028391" />
    </Mention>
    <Mention id="M75" len="17" reason="from_drug_use" section="S1" start="3969" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscular weakness" meddra_llt_id="10028372" meddra_pt="Muscular weakness" meddra_pt_id="10028372" />
    </Mention>
    <Mention id="M76" len="25" reason="from_drug_use" section="S1" start="4083" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Musculoskeletal stiffness" meddra_llt_id="10052904" meddra_pt="Musculoskeletal stiffness" meddra_pt_id="10052904" />
    </Mention>
    <Mention id="M10" len="26" reason="general_term" section="S1" start="4193" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M77" len="8" reason="from_drug_use" section="S1" start="4243" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M11" len="18" reason="general_term" section="S1" start="4353" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder vascular" meddra_llt_id="10013282" meddra_pt="Angiopathy" meddra_pt_id="10059245" />
    </Mention>
    <Mention id="M78" len="9" reason="from_drug_use" section="S1" start="4403" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hot flush" meddra_llt_id="10060800" meddra_pt="Hot flush" meddra_pt_id="10060800" />
    </Mention>
    <Mention id="M79" len="12" reason="from_drug_use" section="S1" start="4517" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M12" len="24" reason="general_term" section="S1" start="4627" type="NonOSE_AE">
      <Normalization meddra_llt="Nervous system disorder" meddra_llt_id="10029202" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M80" len="8" reason="from_drug_use" section="S1" start="4677" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Headache" meddra_llt_id="10019211" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Mention>
    <Mention id="M81" len="9" reason="from_drug_use" section="S1" start="4791" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M82" len="23" reason="from_drug_use" section="S1" start="4905" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Spinal cord compression" meddra_llt_id="10041549" meddra_pt="Spinal cord compression" meddra_pt_id="10041549" />
    </Mention>
    <Mention id="M83" len="21" reason="from_drug_use" section="S1" start="4937" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cauda equina syndrome" meddra_llt_id="10007821" meddra_pt="Cauda equina syndrome" meddra_pt_id="10007821" />
    </Mention>
    <Mention id="M84" len="11" reason="from_drug_use" section="S1" start="5037" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Paresthesia" meddra_llt_id="10033987" meddra_pt="Paraesthesia" meddra_pt_id="10033775" />
    </Mention>
    <Mention id="M194" len="28" reason="from_drug_use" section="S1" start="5151" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mental impairment" meddra_llt_id="10027374" meddra_pt="Mental impairment" meddra_pt_id="10027374" />
    </Mention>
    <Mention id="M85" len="12" reason="from_drug_use" section="S1" start="5265" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypoesthesia" meddra_llt_id="10020976" meddra_pt="Hypoaesthesia" meddra_pt_id="10020937" />
    </Mention>
    <Mention id="M13" len="27" reason="general_term" section="S1" start="5375" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M195" len="37" reason="from_drug_use" section="S1" start="5425" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper respiratory tract infection" meddra_llt_id="10046306" meddra_pt="Upper respiratory tract infection" meddra_pt_id="10046306" />
    </Mention>
    <Mention id="M86" len="23,9" reason="from_drug_use" section="S1" start="5542,5579" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lower respiratory tract infection" meddra_llt_id="10024968" meddra_pt="Lower respiratory tract infection" meddra_pt_id="10024968" />
    </Mention>
    <Mention id="M87" len="14" reason="from_drug_use" section="S1" start="5574" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lung infection" meddra_llt_id="10061229" meddra_pt="Lung infection" meddra_pt_id="10061229" />
    </Mention>
    <Mention id="M14" len="21" reason="general_term" section="S1" start="5664" type="NonOSE_AE">
      <Normalization meddra_llt="Psychiatric disorder NOS" meddra_llt_id="10037174" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M88" len="8" reason="from_drug_use" section="S1" start="5714" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M89" len="7" reason="from_drug_use" section="S1" start="5828" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M15" len="27" reason="general_term" section="S1" start="5938" type="NonOSE_AE">
      <Normalization meddra_llt="Renal disorder" meddra_llt_id="10038428" meddra_pt="Renal disorder" meddra_pt_id="10038428" />
    </Mention>
    <Mention id="M90" len="9" reason="from_drug_use" section="S1" start="5988" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hematuria" meddra_llt_id="10019450" meddra_pt="Haematuria" meddra_pt_id="10018867" />
    </Mention>
    <Mention id="M91" len="11" reason="from_drug_use" section="S1" start="6102" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pollakiuria" meddra_llt_id="10036018" meddra_pt="Pollakiuria" meddra_pt_id="10036018" />
    </Mention>
    <Mention id="M16" len="46" reason="general_term" section="S1" start="6212" type="NonOSE_AE">
      <Normalization meddra_llt="Injury" meddra_llt_id="10022116" meddra_pt="Injury" meddra_pt_id="10022116" />
    </Mention>
    <Mention id="M92" len="4" reason="from_drug_use" section="S1" start="6269" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fall" meddra_llt_id="10016173" meddra_pt="Fall" meddra_pt_id="10016173" />
    </Mention>
    <Mention id="M93" len="24" reason="from_drug_use" section="S1" start="6383" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ill-defined fractures of bones of trunk" meddra_llt_id="10021350" meddra_pt="Fracture" meddra_pt_id="10017076" />
    </Mention>
    <Mention id="M17" len="38" reason="general_term" section="S1" start="6493" type="NonOSE_AE">
      <Normalization meddra_llt="Other disorders of skin and subcutaneous tissue" meddra_llt_id="10032001" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M94" len="8" reason="from_drug_use" section="S1" start="6543" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pruritus" meddra_llt_id="10037087" meddra_pt="Pruritus" meddra_pt_id="10037087" />
    </Mention>
    <Mention id="M95" len="8" reason="from_drug_use" section="S1" start="6657" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry skin" meddra_llt_id="10013786" meddra_pt="Dry skin" meddra_pt_id="10013786" />
    </Mention>
    <Mention id="M18" len="21" reason="general_term" section="S1" start="6767" type="NonOSE_AE">
      <Normalization meddra_llt="Respiratory disorder" meddra_llt_id="10038683" meddra_pt="Respiratory disorder" meddra_pt_id="10038683" />
    </Mention>
    <Mention id="M96" len="9" reason="from_drug_use" section="S1" start="6817" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Epistaxis" meddra_llt_id="10015090" meddra_pt="Epistaxis" meddra_pt_id="10015090" />
    </Mention>
    <Mention id="M97" len="8" reason="from_drug_use" section="S1" start="6956" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Asthenia" meddra_llt_id="10003549" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M98" len="7" reason="from_drug_use" section="S1" start="6969" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M99" len="9" reason="from_drug_use" section="S1" start="6993" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M100" len="7" reason="from_drug_use" section="S1" start="7007" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vertigo" meddra_llt_id="10047340" meddra_pt="Vertigo" meddra_pt_id="10047340" />
    </Mention>
    <Mention id="M101" len="7" reason="from_drug_use" section="S1" start="7031" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Amnesia" meddra_llt_id="10001949" meddra_pt="Amnesia" meddra_pt_id="10001949" />
    </Mention>
    <Mention id="M102" len="17" reason="from_drug_use" section="S1" start="7040" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Memory impairment" meddra_llt_id="10027175" meddra_pt="Memory impairment" meddra_pt_id="10027175" />
    </Mention>
    <Mention id="M103" len="18" reason="from_drug_use" section="S1" start="7059" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cognitive disorder" meddra_llt_id="10057668" meddra_pt="Cognitive disorder" meddra_pt_id="10057668" />
    </Mention>
    <Mention id="M104" len="24" reason="from_drug_use" section="S1" start="7083" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disturbance in attention" meddra_llt_id="10013496" meddra_pt="Disturbance in attention" meddra_pt_id="10013496" />
    </Mention>
    <Mention id="M105" len="15" reason="from_drug_use" section="S1" start="7124" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nasopharyngitis" meddra_llt_id="10028810" meddra_pt="Nasopharyngitis" meddra_pt_id="10028810" />
    </Mention>
    <Mention id="M106" len="33" reason="from_drug_use" section="S1" start="7141" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper respiratory tract infection" meddra_llt_id="10046306" meddra_pt="Upper respiratory tract infection" meddra_pt_id="10046306" />
    </Mention>
    <Mention id="M107" len="9" reason="from_drug_use" section="S1" start="7176" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sinusitis" meddra_llt_id="10040753" meddra_pt="Sinusitis" meddra_pt_id="10040753" />
    </Mention>
    <Mention id="M108" len="8" reason="from_drug_use" section="S1" start="7187" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rhinitis" meddra_llt_id="10039083" meddra_pt="Rhinitis" meddra_pt_id="10039083" />
    </Mention>
    <Mention id="M109" len="11" reason="from_drug_use" section="S1" start="7197" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pharyngitis" meddra_llt_id="10034835" meddra_pt="Pharyngitis" meddra_pt_id="10034835" />
    </Mention>
    <Mention id="M110" len="10" reason="from_drug_use" section="S1" start="7214" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Laryngitis" meddra_llt_id="10023874" meddra_pt="Laryngitis" meddra_pt_id="10023874" />
    </Mention>
    <Mention id="M111" len="9" reason="from_drug_use" section="S1" start="7241" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pneumonia" meddra_llt_id="10035664" meddra_pt="Pneumonia" meddra_pt_id="10035664" />
    </Mention>
    <Mention id="M112" len="33" reason="from_drug_use" section="S1" start="7252" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lower respiratory tract infection" meddra_llt_id="10024968" meddra_pt="Lower respiratory tract infection" meddra_pt_id="10024968" />
    </Mention>
    <Mention id="M113" len="10" reason="from_drug_use" section="S1" start="7287" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bronchitis" meddra_llt_id="10006451" meddra_pt="Bronchitis" meddra_pt_id="10006451" />
    </Mention>
    <Mention id="M114" len="14" reason="from_drug_use" section="S1" start="7303" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lung infection" meddra_llt_id="10061229" meddra_pt="Lung infection" meddra_pt_id="10061229" />
    </Mention>
    <Mention id="M5" len="15" reason="indication" section="S1" start="7447" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hormone-refractory prostate cancer" meddra_llt_id="10062904" meddra_pt="Hormone-refractory prostate cancer" meddra_pt_id="10062904" />
    </Mention>
    <Mention id="M50" len="22" reason="AE_only_as_instruction" section="S1" start="7490" type="NonOSE_AE">
      <Normalization meddra_llt="Chemotherapy" meddra_llt_id="10061758" meddra_pt="Chemotherapy" meddra_pt_id="10061758" />
    </Mention>
    <Mention id="M204" len="7" reason="from_drug_use" section="S1" start="7969" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M205" len="8" reason="from_drug_use" section="S1" start="7977" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Asthenia" meddra_llt_id="10003549" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M19" len="17" reason="general_term" section="S1" start="8440" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M196" len="19" reason="from_drug_use" section="S1" start="8490" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Asthenia" meddra_llt_id="10003549" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M115" len="16" reason="from_drug_use" section="S1" start="8603" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Peripheral edema" meddra_llt_id="10034570" meddra_pt="Oedema peripheral" meddra_pt_id="10030124" />
    </Mention>
    <Mention id="M20" len="47" reason="general_term" section="S1" start="8712" type="NonOSE_AE">
      <Normalization meddra_llt="Musculoskeletal disorder" meddra_llt_id="10048592" meddra_pt="Musculoskeletal disorder" meddra_pt_id="10048592" />
    </Mention>
    <Mention id="M116" len="9" reason="from_drug_use" section="S1" start="8770" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain back" meddra_llt_id="10033380" meddra_pt="Back pain" meddra_pt_id="10003988" />
    </Mention>
    <Mention id="M117" len="10" reason="from_drug_use" section="S1" start="8883" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Arthralgia" meddra_llt_id="10003239" meddra_pt="Arthralgia" meddra_pt_id="10003239" />
    </Mention>
    <Mention id="M21" len="26" reason="general_term" section="S1" start="8992" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M118" len="12" reason="from_drug_use" section="S1" start="9042" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M119" len="8" reason="from_drug_use" section="S1" start="9155" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M22" len="18" reason="general_term" section="S1" start="9264" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder vascular" meddra_llt_id="10013282" meddra_pt="Angiopathy" meddra_pt_id="10059245" />
    </Mention>
    <Mention id="M120" len="9" reason="from_drug_use" section="S1" start="9314" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hot flush" meddra_llt_id="10060800" meddra_pt="Hot flush" meddra_pt_id="10060800" />
    </Mention>
    <Mention id="M121" len="12" reason="from_drug_use" section="S1" start="9427" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M23" len="24" reason="general_term" section="S1" start="9536" type="NonOSE_AE">
      <Normalization meddra_llt="Nervous system disorder" meddra_llt_id="10029202" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M122" len="9" reason="from_drug_use" section="S1" start="9586" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M123" len="8" reason="from_drug_use" section="S1" start="9699" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Headache" meddra_llt_id="10019211" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Mention>
    <Mention id="M124" len="9" reason="from_drug_use" section="S1" start="9812" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dysgeusia" meddra_llt_id="10013911" meddra_pt="Dysgeusia" meddra_pt_id="10013911" />
    </Mention>
    <Mention id="M197" len="28" reason="from_drug_use" section="S1" start="9925" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mental impairment" meddra_llt_id="10027374" meddra_pt="Mental impairment" meddra_pt_id="10027374" />
    </Mention>
    <Mention id="M125" len="22" reason="from_drug_use" section="S1" start="10038" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Restless legs syndrome" meddra_llt_id="10058920" meddra_pt="Restless legs syndrome" meddra_pt_id="10058920" />
    </Mention>
    <Mention id="M24" len="21" reason="general_term" section="S1" start="10147" type="NonOSE_AE">
      <Normalization meddra_llt="Respiratory disorder" meddra_llt_id="10038683" meddra_pt="Respiratory disorder" meddra_pt_id="10038683" />
    </Mention>
    <Mention id="M126" len="8" reason="from_drug_use" section="S1" start="10197" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspnoea" meddra_llt_id="10013968" meddra_pt="Dyspnoea" meddra_pt_id="10013968" />
    </Mention>
    <Mention id="M25" len="27" reason="general_term" section="S1" start="10306" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M198" len="37" reason="from_drug_use" section="S1" start="10356" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper respiratory tract infection" meddra_llt_id="10046306" meddra_pt="Upper respiratory tract infection" meddra_pt_id="10046306" />
    </Mention>
    <Mention id="M127" len="23,9" reason="from_drug_use" section="S1" start="10472,10509" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lower respiratory tract infection" meddra_llt_id="10024968" meddra_pt="Lower respiratory tract infection" meddra_pt_id="10024968" />
    </Mention>
    <Mention id="M128" len="14" reason="from_drug_use" section="S1" start="10504" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lung infection" meddra_llt_id="10061229" meddra_pt="Lung infection" meddra_pt_id="10061229" />
    </Mention>
    <Mention id="M26" len="21" reason="general_term" section="S1" start="10593" type="NonOSE_AE">
      <Normalization meddra_llt="Psychiatric disorder NOS" meddra_llt_id="10037174" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M129" len="8" reason="from_drug_use" section="S1" start="10643" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M27" len="27" reason="general_term" section="S1" start="10752" type="NonOSE_AE">
      <Normalization meddra_llt="Renal disorder" meddra_llt_id="10038428" meddra_pt="Renal disorder" meddra_pt_id="10038428" />
    </Mention>
    <Mention id="M130" len="9" reason="from_drug_use" section="S1" start="10802" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hematuria" meddra_llt_id="10019450" meddra_pt="Haematuria" meddra_pt_id="10018867" />
    </Mention>
    <Mention id="M28" len="46" reason="general_term" section="S1" start="10911" type="NonOSE_AE">
      <Normalization meddra_llt="Injury" meddra_llt_id="10022116" meddra_pt="Injury" meddra_pt_id="10022116" />
    </Mention>
    <Mention id="M131" len="4" reason="from_drug_use" section="S1" start="10968" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fall" meddra_llt_id="10016173" meddra_pt="Fall" meddra_pt_id="10016173" />
    </Mention>
    <Mention id="M132" len="25" reason="from_drug_use" section="S1" start="11081" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fracture" meddra_llt_id="10017076" meddra_pt="Fracture" meddra_pt_id="10017076" />
    </Mention>
    <Mention id="M29" len="34" reason="general_term" section="S1" start="11190" type="NonOSE_AE">
      <Normalization meddra_llt="Unspecified disorder of metabolism" meddra_llt_id="10045811" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M133" len="18" reason="from_drug_use" section="S1" start="11240" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Decreased appetite" meddra_llt_id="10061428" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M30" len="14" reason="general_term" section="S1" start="11349" type="NonOSE_AE">
      <Normalization meddra_llt="Investigation" meddra_llt_id="10062026" meddra_pt="Investigation" meddra_pt_id="10062026" />
    </Mention>
    <Mention id="M134" len="16" reason="from_drug_use" section="S1" start="11399" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight decreased" meddra_llt_id="10047895" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M31" len="40" reason="general_term" section="S1" start="11508" type="NonOSE_AE">
      <Normalization meddra_llt="Reproductive tract disorder" meddra_llt_id="10061483" meddra_pt="Reproductive tract disorder" meddra_pt_id="10061483" />
      <Normalization meddra_pt="Reproductive toxicity" meddra_pt_id="10074268" />
    </Mention>
    <Mention id="M135" len="12" reason="from_drug_use" section="S1" start="11559" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gynecomastia" meddra_llt_id="10018801" meddra_pt="Gynaecomastia" meddra_pt_id="10018800" />
    </Mention>
    <Mention id="M136" len="8" reason="from_drug_use" section="S1" start="11697" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Asthenia" meddra_llt_id="10003549" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M137" len="7" reason="from_drug_use" section="S1" start="11710" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M138" len="9" reason="from_drug_use" section="S1" start="11734" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M139" len="7" reason="from_drug_use" section="S1" start="11748" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vertigo" meddra_llt_id="10047340" meddra_pt="Vertigo" meddra_pt_id="10047340" />
    </Mention>
    <Mention id="M140" len="7" reason="from_drug_use" section="S1" start="11772" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Amnesia" meddra_llt_id="10001949" meddra_pt="Amnesia" meddra_pt_id="10001949" />
    </Mention>
    <Mention id="M141" len="17" reason="from_drug_use" section="S1" start="11781" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Memory impairment" meddra_llt_id="10027175" meddra_pt="Memory impairment" meddra_pt_id="10027175" />
    </Mention>
    <Mention id="M142" len="18" reason="from_drug_use" section="S1" start="11800" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cognitive disorder" meddra_llt_id="10057668" meddra_pt="Cognitive disorder" meddra_pt_id="10057668" />
    </Mention>
    <Mention id="M143" len="24" reason="from_drug_use" section="S1" start="11824" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disturbance in attention" meddra_llt_id="10013496" meddra_pt="Disturbance in attention" meddra_pt_id="10013496" />
    </Mention>
    <Mention id="M144" len="7" reason="from_drug_use" section="S1" start="11865" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspnea" meddra_llt_id="10013963" meddra_pt="Dyspnoea" meddra_pt_id="10013968" />
    </Mention>
    <Mention id="M145" len="18" reason="from_drug_use" section="S1" start="11874" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspnea exertional" meddra_llt_id="10013966" meddra_pt="Dyspnoea exertional" meddra_pt_id="10013971" />
    </Mention>
    <Mention id="M146" len="15" reason="from_drug_use" section="S1" start="11898" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspnea at rest" meddra_llt_id="10079027" meddra_pt="Dyspnoea at rest" meddra_pt_id="10013969" />
    </Mention>
    <Mention id="M147" len="15" reason="from_drug_use" section="S1" start="11930" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nasopharyngitis" meddra_llt_id="10028810" meddra_pt="Nasopharyngitis" meddra_pt_id="10028810" />
    </Mention>
    <Mention id="M148" len="33" reason="from_drug_use" section="S1" start="11947" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper respiratory tract infection" meddra_llt_id="10046306" meddra_pt="Upper respiratory tract infection" meddra_pt_id="10046306" />
    </Mention>
    <Mention id="M149" len="9" reason="from_drug_use" section="S1" start="11982" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sinusitis" meddra_llt_id="10040753" meddra_pt="Sinusitis" meddra_pt_id="10040753" />
    </Mention>
    <Mention id="M150" len="8" reason="from_drug_use" section="S1" start="11993" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rhinitis" meddra_llt_id="10039083" meddra_pt="Rhinitis" meddra_pt_id="10039083" />
    </Mention>
    <Mention id="M151" len="11" reason="from_drug_use" section="S1" start="12003" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pharyngitis" meddra_llt_id="10034835" meddra_pt="Pharyngitis" meddra_pt_id="10034835" />
    </Mention>
    <Mention id="M152" len="10" reason="from_drug_use" section="S1" start="12020" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Laryngitis" meddra_llt_id="10023874" meddra_pt="Laryngitis" meddra_pt_id="10023874" />
    </Mention>
    <Mention id="M153" len="9" reason="from_drug_use" section="S1" start="12047" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pneumonia" meddra_llt_id="10035664" meddra_pt="Pneumonia" meddra_pt_id="10035664" />
    </Mention>
    <Mention id="M154" len="33" reason="from_drug_use" section="S1" start="12058" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lower respiratory tract infection" meddra_llt_id="10024968" meddra_pt="Lower respiratory tract infection" meddra_pt_id="10024968" />
    </Mention>
    <Mention id="M155" len="10" reason="from_drug_use" section="S1" start="12093" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bronchitis" meddra_llt_id="10006451" meddra_pt="Bronchitis" meddra_pt_id="10006451" />
    </Mention>
    <Mention id="M156" len="14" reason="from_drug_use" section="S1" start="12109" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lung infection" meddra_llt_id="10061229" meddra_pt="Lung infection" meddra_pt_id="10061229" />
    </Mention>
    <Mention id="M6" len="15" reason="indication" section="S1" start="12257" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hormone-refractory prostate cancer" meddra_llt_id="10062904" meddra_pt="Hormone-refractory prostate cancer" meddra_pt_id="10062904" />
    </Mention>
    <Mention id="M51" len="22" reason="AE_only_as_instruction" section="S1" start="12300" type="NonOSE_AE">
      <Normalization meddra_llt="Chemotherapy" meddra_llt_id="10061758" meddra_pt="Chemotherapy" meddra_pt_id="10061758" />
    </Mention>
    <Mention id="M157" len="9" reason="from_drug_use" section="S1" start="12704" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain back" meddra_llt_id="10033380" meddra_pt="Back pain" meddra_pt_id="10003988" />
    </Mention>
    <Mention id="M158" len="21" reason="from_drug_use" section="S1" start="12718" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fracture pathological" meddra_llt_id="10017272" meddra_pt="Pathological fracture" meddra_pt_id="10034156" />
    </Mention>
    <Mention id="M32" len="17" reason="general_term" section="S1" start="13340" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M199" len="19" reason="from_drug_use" section="S1" start="13390" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Asthenia" meddra_llt_id="10003549" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M33" len="47" reason="general_term" section="S1" start="13500" type="NonOSE_AE">
      <Normalization meddra_llt="Musculoskeletal disorder" meddra_llt_id="10048592" meddra_pt="Musculoskeletal disorder" meddra_pt_id="10048592" />
    </Mention>
    <Mention id="M159" len="9" reason="from_drug_use" section="S1" start="13558" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain back" meddra_llt_id="10033380" meddra_pt="Back pain" meddra_pt_id="10003988" />
    </Mention>
    <Mention id="M160" len="20" reason="from_drug_use" section="S1" start="13672" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Musculoskeletal pain" meddra_llt_id="10028391" meddra_pt="Musculoskeletal pain" meddra_pt_id="10028391" />
    </Mention>
    <Mention id="M34" len="18" reason="general_term" section="S1" start="13782" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder vascular" meddra_llt_id="10013282" meddra_pt="Angiopathy" meddra_pt_id="10059245" />
    </Mention>
    <Mention id="M161" len="9" reason="from_drug_use" section="S1" start="13832" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hot flush" meddra_llt_id="10060800" meddra_pt="Hot flush" meddra_pt_id="10060800" />
    </Mention>
    <Mention id="M162" len="12" reason="from_drug_use" section="S1" start="13946" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M35" len="26" reason="general_term" section="S1" start="14056" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M163" len="6" reason="from_drug_use" section="S1" start="14106" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M164" len="12" reason="from_drug_use" section="S1" start="14220" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M165" len="8" reason="from_drug_use" section="S1" start="14334" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M36" len="27" reason="general_term" section="S1" start="14444" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M166" len="33" reason="from_drug_use" section="S1" start="14494" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper respiratory tract infection" meddra_llt_id="10046306" meddra_pt="Upper respiratory tract infection" meddra_pt_id="10046306" />
    </Mention>
    <Mention id="M37" len="15" reason="general_term" section="S1" start="14604" type="NonOSE_AE">
      <Normalization meddra_llt="Investigation" meddra_llt_id="10062026" meddra_pt="Investigation" meddra_pt_id="10062026" />
    </Mention>
    <Mention id="M167" len="11" reason="from_drug_use" section="S1" start="14654" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight loss" meddra_llt_id="10047900" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M168" len="8" reason="from_drug_use" section="S1" start="14793" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Asthenia" meddra_llt_id="10003549" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M169" len="7" reason="from_drug_use" section="S1" start="14806" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M170" len="20" reason="from_drug_use" section="S1" start="14829" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Musculoskeletal pain" meddra_llt_id="10028391" meddra_pt="Musculoskeletal pain" meddra_pt_id="10028391" />
    </Mention>
    <Mention id="M171" len="17" reason="from_drug_use" section="S1" start="14854" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain in extremity" meddra_llt_id="10033425" meddra_pt="Pain in extremity" meddra_pt_id="10033425" />
    </Mention>
    <Mention id="M172" len="15" reason="from_drug_use" section="S1" start="14887" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nasopharyngitis" meddra_llt_id="10028810" meddra_pt="Nasopharyngitis" meddra_pt_id="10028810" />
    </Mention>
    <Mention id="M173" len="33" reason="from_drug_use" section="S1" start="14904" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper respiratory tract infection" meddra_llt_id="10046306" meddra_pt="Upper respiratory tract infection" meddra_pt_id="10046306" />
    </Mention>
    <Mention id="M174" len="9" reason="from_drug_use" section="S1" start="14939" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sinusitis" meddra_llt_id="10040753" meddra_pt="Sinusitis" meddra_pt_id="10040753" />
    </Mention>
    <Mention id="M175" len="8" reason="from_drug_use" section="S1" start="14950" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rhinitis" meddra_llt_id="10039083" meddra_pt="Rhinitis" meddra_pt_id="10039083" />
    </Mention>
    <Mention id="M176" len="11" reason="from_drug_use" section="S1" start="14960" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pharyngitis" meddra_llt_id="10034835" meddra_pt="Pharyngitis" meddra_pt_id="10034835" />
    </Mention>
    <Mention id="M177" len="10" reason="from_drug_use" section="S1" start="14977" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Laryngitis" meddra_llt_id="10023874" meddra_pt="Laryngitis" meddra_pt_id="10023874" />
    </Mention>
    <Mention id="M178" len="11" reason="from_drug_use" section="S1" start="15104" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M179" len="16" reason="from_drug_use" section="S1" start="15267" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombocytopenia" meddra_llt_id="10043554" meddra_pt="Thrombocytopenia" meddra_pt_id="10043554" />
    </Mention>
    <Mention id="M7" len="17" reason="AE_rate_lteq_placebo" section="S1" start="15408" type="NonOSE_AE">
      <Normalization meddra_llt="ALT increased" meddra_llt_id="10001845" meddra_pt="Alanine aminotransferase increased" meddra_pt_id="10001551" />
    </Mention>
    <Mention id="M180" len="23" reason="from_drug_use" section="S1" start="15560" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bilirubin elevated" meddra_llt_id="10004688" meddra_pt="Blood bilirubin increased" meddra_pt_id="10005364" />
    </Mention>
    <Mention id="M38" len="4" reason="general_term" section="S1" start="15820" type="NonOSE_AE">
      <Normalization meddra_llt="Died in sleep" meddra_llt_id="10012771" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M39" len="10" reason="AE_only_as_instruction" section="S1" start="15830" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M40" len="6" reason="AE_only_as_instruction" section="S1" start="15844" type="NonOSE_AE">
      <Normalization meddra_llt="Sepsis" meddra_llt_id="10040047" meddra_pt="Sepsis" meddra_pt_id="10040047" />
    </Mention>
    <Mention id="M52" len="9" reason="AE_only_as_instruction" section="S1" start="15912" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M41" len="5" reason="general_term" section="S1" start="15935" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M181" len="5" reason="from_drug_use" section="S1" start="16040" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fall" meddra_llt_id="10016173" meddra_pt="Fall" meddra_pt_id="10016173" />
    </Mention>
    <Mention id="M182" len="21" reason="from_drug_use" section="S1" start="16056" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Injury" meddra_llt_id="10022116" meddra_pt="Injury" meddra_pt_id="10022116" />
    </Mention>
    <Mention id="M42" len="5" reason="AE_only_as_instruction" section="S1" start="16175" type="NonOSE_AE">
      <Normalization meddra_llt="Fall" meddra_llt_id="10016173" meddra_pt="Fall" meddra_pt_id="10016173" />
    </Mention>
    <Mention id="M43" len="21" reason="negation" section="S1" start="16206" type="NonOSE_AE">
      <Normalization meddra_llt="Consciousness loss of" meddra_llt_id="10010772" meddra_pt="Loss of consciousness" meddra_pt_id="10024855" />
    </Mention>
    <Mention id="M44" len="7" reason="negation" section="S1" start="16231" type="NonOSE_AE">
      <Normalization meddra_llt="Seizure" meddra_llt_id="10039906" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M183" len="21" reason="from_drug_use" section="S1" start="16240" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Injury" meddra_llt_id="10022116" meddra_pt="Injury" meddra_pt_id="10022116" />
    </Mention>
    <Mention id="M200" len="12,24" reason="from_drug_use" section="S1" start="16240,16324" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fracture" meddra_llt_id="10017076" meddra_pt="Fracture" meddra_pt_id="10017076" />
    </Mention>
    <Mention id="M201" len="12,9" reason="from_drug_use" section="S1" start="16240,16370" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Traumatic hematoma" meddra_llt_id="10044525" meddra_pt="Traumatic haematoma" meddra_pt_id="10044522" />
    </Mention>
    <Mention id="M202" len="12,14" reason="from_drug_use" section="S1" start="16240,16350" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Joint injury" meddra_llt_id="10060820" meddra_pt="Joint injury" meddra_pt_id="10060820" />
    </Mention>
    <Mention id="M184" len="12" reason="from_drug_use" section="S1" start="16451" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M45" len="19" reason="negation" section="S1" start="16575" type="NonOSE_AE">
      <Normalization meddra_llt="Crisis hypertensive" meddra_llt_id="10011395" meddra_pt="Hypertensive crisis" meddra_pt_id="10020802" />
    </Mention>
    <Mention id="M1" len="12" reason="preexisting_condition_or_risk_factor" section="S1" start="16615" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M206" len="12" reason="from_drug_use" section="S1" start="16655" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M46" len="15" reason="general_term" section="S1" start="17072" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M185" len="16" reason="from_drug_use" section="S1" start="17090" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drug hypersensitivity" meddra_llt_id="10013700" meddra_pt="Drug hypersensitivity" meddra_pt_id="10013700" />
      <Normalization meddra_pt="Hypersensitivity" meddra_pt_id="10020751" />
    </Mention>
    <Mention id="M186" len="12" reason="from_drug_use" section="S1" start="17108" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tongue edema" meddra_llt_id="10043955" meddra_pt="Tongue oedema" meddra_pt_id="10043967" />
    </Mention>
    <Mention id="M187" len="9" reason="from_drug_use" section="S1" start="17122" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Edema lip" meddra_llt_id="10014231" meddra_pt="Lip oedema" meddra_pt_id="10024558" />
    </Mention>
    <Mention id="M188" len="16" reason="from_drug_use" section="S1" start="17137" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pharyngeal edema" meddra_llt_id="10054544" meddra_pt="Pharyngeal oedema" meddra_pt_id="10034829" />
    </Mention>
    <Mention id="M47" len="26" reason="general_term" section="S1" start="17159" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M189" len="8" reason="from_drug_use" section="S1" start="17188" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M48" len="22" reason="general_term" section="S1" start="17201" type="NonOSE_AE">
      <Normalization meddra_llt="Neurological disorder NOS" meddra_llt_id="10029298" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M203" len="50" reason="from_drug_use" section="S1" start="17226" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Posterior reversible encephalopathy syndrome" meddra_llt_id="10071066" meddra_pt="Posterior reversible encephalopathy syndrome" meddra_pt_id="10071066" />
    </Mention>
    <Mention id="M49" len="38" reason="general_term" section="S1" start="17282" type="NonOSE_AE">
      <Normalization meddra_llt="Other disorders of skin and subcutaneous tissue" meddra_llt_id="10032001" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M190" len="4" reason="from_drug_use" section="S1" start="17323" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M242" len="7" reason="from_drug_use" section="S2" start="403" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Seizure" meddra_llt_id="10039906" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M230" len="7" reason="AE_only_as_instruction" section="S2" start="533" type="NonOSE_AE">
      <Normalization meddra_llt="Seizure" meddra_llt_id="10039906" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M243" len="7" reason="from_drug_use" section="S2" start="566" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Seizure" meddra_llt_id="10039906" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M231" len="7" reason="AE_only_as_instruction" section="S2" start="653" type="NonOSE_AE">
      <Normalization meddra_llt="Seizure" meddra_llt_id="10039906" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M232" len="7" reason="AE_only_as_instruction" section="S2" start="712" type="NonOSE_AE">
      <Normalization meddra_llt="Seizure" meddra_llt_id="10039906" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M233" len="7" reason="AE_only_as_instruction" section="S2" start="795" type="NonOSE_AE">
      <Normalization meddra_llt="Seizure" meddra_llt_id="10039906" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M234" len="7" reason="AE_only_as_instruction" section="S2" start="846" type="NonOSE_AE">
      <Normalization meddra_llt="Seizure" meddra_llt_id="10039906" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M244" len="7" reason="from_drug_use" section="S2" start="909" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Seizure" meddra_llt_id="10039906" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M245" len="7" reason="from_drug_use" section="S2" start="963" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Seizure" meddra_llt_id="10039906" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M235" len="7" reason="AE_only_as_instruction" section="S2" start="1028" type="NonOSE_AE">
      <Normalization meddra_llt="Seizure" meddra_llt_id="10039906" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M236" len="8" reason="AE_only_as_instruction" section="S2" start="1108" type="NonOSE_AE">
      <Normalization meddra_llt="Seizures" meddra_llt_id="10039910" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M237" len="27" reason="AE_only_as_instruction" section="S2" start="1240" type="NonOSE_AE">
      <Normalization meddra_llt="Lowered seizure threshold during ECT" meddra_llt_id="10024983" meddra_pt="Convulsive threshold lowered" meddra_pt_id="10010927" />
    </Mention>
    <Mention id="M207" len="30" reason="preexisting_condition_or_risk_factor" section="S2" start="1288" type="Not_AE_Candidate">
      <Normalization meddra_llt="Traumatic brain injury" meddra_llt_id="10060690" meddra_pt="Craniocerebral injury" meddra_pt_id="10070976" />
    </Mention>
    <Mention id="M208" len="24" reason="preexisting_condition_or_risk_factor" section="S2" start="1339" type="Not_AE_Candidate">
      <Normalization meddra_llt="Accident cerebrovascular" meddra_llt_id="10000374" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M209" len="25" reason="preexisting_condition_or_risk_factor" section="S2" start="1367" type="Not_AE_Candidate">
      <Normalization meddra_llt="Transient ischemic attack" meddra_llt_id="10072760" meddra_pt="Transient ischaemic attack" meddra_pt_id="10044390" />
    </Mention>
    <Mention id="M210" len="19" reason="preexisting_condition_or_risk_factor" section="S2" start="1406" type="Not_AE_Candidate">
      <Normalization meddra_llt="Alzheimer's disease" meddra_llt_id="10001896" meddra_pt="Dementia Alzheimer's type" meddra_pt_id="10012271" />
    </Mention>
    <Mention id="M211" len="10" reason="preexisting_condition_or_risk_factor" section="S2" start="1427" type="Not_AE_Candidate">
      <Normalization meddra_llt="Meningioma" meddra_llt_id="10027191" meddra_pt="Meningioma" meddra_pt_id="10027191" />
    </Mention>
    <Mention id="M212" len="22" reason="preexisting_condition_or_risk_factor" section="S2" start="1442" type="Not_AE_Candidate">
      <Normalization meddra_llt="Leptomeningeal disease" meddra_llt_id="10070973" meddra_pt="Metastases to meninges" meddra_pt_id="10051696" />
    </Mention>
    <Mention id="M213" len="15" reason="indication" section="S2" start="1470" type="Not_AE_Candidate">
      <Normalization meddra_llt="Prostate cancer" meddra_llt_id="10060862" meddra_pt="Prostate cancer" meddra_pt_id="10060862" />
    </Mention>
    <Mention id="M214" len="21" reason="preexisting_condition_or_risk_factor" section="S2" start="1499" type="Not_AE_Candidate">
      <Normalization meddra_llt="Consciousness loss of" meddra_llt_id="10010772" meddra_pt="Loss of consciousness" meddra_pt_id="10024855" />
    </Mention>
    <Mention id="M215" len="7" reason="preexisting_condition_or_risk_factor" section="S2" start="1564" type="Not_AE_Candidate">
      <Normalization meddra_llt="Seizure" meddra_llt_id="10039906" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M216" len="35" reason="preexisting_condition_or_risk_factor" section="S2" start="1587" type="Not_AE_Candidate">
      <Normalization meddra_llt="Brain lesion" meddra_llt_id="10067294" meddra_pt="Central nervous system lesion" meddra_pt_id="10051290" />
    </Mention>
    <Mention id="M217" len="26" reason="preexisting_condition_or_risk_factor" section="S2" start="1635" type="Not_AE_Candidate">
      <Normalization meddra_llt="Arteriovenous malformation" meddra_llt_id="10003193" meddra_pt="Arteriovenous malformation" meddra_pt_id="10003193" />
    </Mention>
    <Mention id="M218" len="15" reason="preexisting_condition_or_risk_factor" section="S2" start="1677" type="Not_AE_Candidate">
      <Normalization meddra_llt="Central nervous system infection" meddra_llt_id="10061036" meddra_pt="Central nervous system infection" meddra_pt_id="10061036" />
    </Mention>
    <Mention id="M219" len="7" reason="AE_only_as_instruction" section="S2" start="1815" type="NonOSE_AE">
      <Normalization meddra_llt="Seizure" meddra_llt_id="10039906" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M238" len="21" reason="AE_only_as_instruction" section="S2" start="1891" type="NonOSE_AE">
      <Normalization meddra_llt="Consciousness loss of" meddra_llt_id="10010772" meddra_pt="Loss of consciousness" meddra_pt_id="10024855" />
    </Mention>
    <Mention id="M220" len="7" reason="AE_only_as_instruction" section="S2" start="2025" type="NonOSE_AE">
      <Normalization meddra_llt="Seizure" meddra_llt_id="10039906" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M246" len="50" reason="from_drug_use" section="S2" start="2144" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Posterior reversible encephalopathy syndrome" meddra_llt_id="10071066" meddra_pt="Posterior reversible encephalopathy syndrome" meddra_pt_id="10071066" />
    </Mention>
    <Mention id="M239" len="4" reason="AE_only_as_instruction" section="S2" start="2264" type="NonOSE_AE">
      <Normalization meddra_llt="Posterior reversible encephalopathy syndrome" meddra_llt_id="10071066" meddra_pt="Posterior reversible encephalopathy syndrome" meddra_pt_id="10071066" />
    </Mention>
    <Mention id="M240" len="21" reason="AE_only_as_instruction" section="S2" start="2274" type="NonOSE_AE">
      <Normalization meddra_llt="Neurological disorder NOS" meddra_llt_id="10029298" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M221" len="7" reason="manifestation_or_complication" section="S2" start="2355" type="NonOSE_AE">
      <Normalization meddra_llt="Seizure" meddra_llt_id="10039906" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M222" len="8" reason="manifestation_or_complication" section="S2" start="2364" type="NonOSE_AE">
      <Normalization meddra_llt="Headache" meddra_llt_id="10019211" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Mention>
    <Mention id="M223" len="8" reason="manifestation_or_complication" section="S2" start="2374" type="NonOSE_AE">
      <Normalization meddra_llt="Lethargy" meddra_llt_id="10024264" meddra_pt="Lethargy" meddra_pt_id="10024264" />
    </Mention>
    <Mention id="M224" len="9" reason="manifestation_or_complication" section="S2" start="2384" type="NonOSE_AE">
      <Normalization meddra_llt="Confusion" meddra_llt_id="10010300" meddra_pt="Confusional state" meddra_pt_id="10010305" />
    </Mention>
    <Mention id="M225" len="9" reason="manifestation_or_complication" section="S2" start="2395" type="NonOSE_AE">
      <Normalization meddra_llt="Blindness" meddra_llt_id="10005169" meddra_pt="Blindness" meddra_pt_id="10005169" />
    </Mention>
    <Mention id="M226" len="6,12" reason="manifestation_or_complication" section="S2" start="2416,2440" type="NonOSE_AE">
      <Normalization meddra_llt="Visual disturbances" meddra_llt_id="10047545" meddra_pt="Visual impairment" meddra_pt_id="10047571" />
    </Mention>
    <Mention id="M227" len="25" reason="manifestation_or_complication" section="S2" start="2427" type="NonOSE_AE">
      <Normalization meddra_llt="Neurological complication" meddra_llt_id="10029296" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M228" len="12" reason="manifestation_or_complication" section="S2" start="2481" type="NonOSE_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M241" len="4" reason="AE_only_as_instruction" section="S2" start="2510" type="NonOSE_AE">
      <Normalization meddra_llt="Posterior reversible encephalopathy syndrome" meddra_llt_id="10071066" meddra_pt="Posterior reversible encephalopathy syndrome" meddra_pt_id="10071066" />
    </Mention>
    <Mention id="M229" len="4" reason="AE_only_as_instruction" section="S2" start="2643" type="NonOSE_AE">
      <Normalization meddra_llt="Posterior reversible encephalopathy syndrome" meddra_llt_id="10071066" meddra_pt="Posterior reversible encephalopathy syndrome" meddra_pt_id="10071066" />
    </Mention>
  </Mentions>
</GoldLabel>